Yadav Ajay Kumar^1,2*, Gnawali Suman², Chapagain Dipak³, Yadav Dipesh Kumar⁴ and Gangbiao Yuan¹

¹Department of Nuclear Medicine, The Second Affiliated Hospital of Chongqing Medical University, China
²Department of Radio-Diagnosis, Imaging and Nuclear Medicine, BP Koirala Memorial Cancer Hospital, Bharatpur, Chitwan, Nepal
³Department of Pathology, BP Koirala Memorial Cancer Hospital, Bharatpur, Chitwan, Nepal
⁴Department of Medical Record, BP Koirala Memorial Cancer Hospital, Bharatpur, Chitwan, Nepal

*Corresponding Author: Yadav Ajay Kumar, Department of Nuclear Medicine, The Second Affiliated Hospital of Chongqing Medical University, China.

Received: June 01, 2021; Published: July 13, 2021

Abstract

  Since last December 2019, there is panic situation all over the world due to COVID-19 pandemic. Due to highly infectious nature of SARS-CoV-2, all other non-communicable diseases treatment is directly affected in most of the hospitals. Most hospitals in epidemic region reduced the non-emergency treatments and other supportive services. Our country Nepal is also vigorously infected by COVID- 19. Before recovering from first wave of that epidemic, there is second wave ofSARS-CoV-2 with double and triple mutant virus which one seems more dangerous than the previous. We are still facing the more panic situation of this epidemic. As a result, it is difficult to manage treatment of cancer patients in hospital in time, which adversely affects the prognosis. To overcome from that issue, our cancer center develops a strategic plan to continue the treatment of patients and at the same time prevention is also important for medical staffs, non-infected patients and visitors. In our study, we included that how our cancer center made a plan to continue treatment of cancer patients, preventive major to hospital staffs and preventive major to visitors with patients. We concluded that adding RT-PCR screening facility and separate COVID isolation ward including all preventive majors regarding COVID-19 to our hospital, makes more impact on cancer patients treatment management during COVID-19 pandemic.

References

1. “Coronavirus resource center”. Jons Hopkins University of Medicine (2021).
2. “COVID-19 Symptoms, Coronavirus Disease”. World Health Organization (WHO).
3. Symptoms, COVID-19, Centers for Disease Control and Prevention (CDC).
4. Jingjing He., et al. “Proportion of asymptomatic coronavirus disease 2019: A systematic review and meta-analysis”. Journal of Medical Virology2 (2021): 820-830.
5. “Covid-19 update portal”. Ministry of Health and population, Government of Nepal (2021).
6. Chen N., et al. “Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study”. Lancet 10223 (2020): 507-513.
7. Kamboj M and Sepkowitz KA. “Nosocomial infections in patients with cancer”. Lancet Oncology 6 (2009): 589-597.
8. Jianbo Tian., et al. “Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study”. Lancet Oncology 7 (2020): 893-903.
9. Xia Y., et al. “Risk of COVID-19 for patients with cancer”. Lancet Oncology 4 (2020): e180.
10. National Testing Guidelines for COVID-19 (Approved Date: 2077/02/20| Approved by Hon. Minister, Ministry of Health and Population Nepal).
11. Ingrid Arevalo-Rodriguez., et al. “False-negative results of initial RT-PCR assays for COVID-19: A systematic review”. PLoS One12 (2020): e0242958.
12. Lu R., et al. “Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding”. Lancet 10224 (2020): 565-574.
13. Wang D., et al. “Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China”. JAMA 11 (2020): 1061-1069.
14. Chua F., et al. “The role of CT in case ascertainment and management of COVID-19 pneumonia in the UK: insights from high-incidence regions”. Lancet Respiratory Medicine5 (2020): 438-440.
15. Xie X., et al. “Chest CT for Typical Coronavirus Disease 2019 (COVID-19) Pneumonia: Relationship to Negative RTPCR Testing”. Radiology2 (2020): E41-45.
16. Wang W., et al. “Detection of SARS-CoV-2 in Different Types of Clinical Specimens”. JAMA18 (2020): 1843-1844.
17. Wolfel R., et al. “Virological assessment of hospitalized patients with COVID-2019”. Nature7809 (2020): 465-469.
18. Tramontana AR., et al. “Oseltamivir resistance in adult oncology and hematology patients infected with pandemic (H1N1) 2009 virus, Australia”. Emerging Infectious Diseases 7 (2010): 1068-1075.
19. Jain S., et al. “Hospitalized patients with 2009 H1N1 influenza in the United States, April-June 2009”. The New England Journal of Medicine20 (2009): 1935-1944.
20. Rischioinfettivo da coronavirus COVID 19: indicazioni per l’oncologia (2020).
21. You B., et al. “The official French guidelines to protect patients with cancer against SARS-CoV-2 infection”. Lancet Oncology (2020): S1470-2045 (20): 30204-7.
22. “COVID-19 rapid guideline: delivery of systemic anticancer treatments”. NICE guideline (2020).
23. “ESMO Guidelines: Cancer patient management during the COVID-19 pandemic” (2020).
24. “COVID-19 patient care information” (2020).
25. “CDC guidance for COVID-19” (2020).
26. Tagliamento M., et al. “Call for ensuring cancer care continuity during COVID-19 pandemic”. ESMO Open3 (2020): e000783.
27. Zhang L., et al. “Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China”. Annals of Oncology7 (2020): 894-901.
28. Lambertini M., et al. “Cancer care during the spread of coronavirus disease 2019 (COVID-19) in Italy: young oncologists' perspective”. ESMO Open2 (2020): e000759.

Citation

Citation: Yadav Ajay Kumar., et al. “Cancer Patients Treatment Management during COVID-19 Pandemic: A Single Center Experience at Bharatpur, Nepal". Acta Scientific Medical Sciences 5.8 (2021): 16-26.

Copyright

Copyright: © 2021 Yadav Ajay Kumar., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.